These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1177 related articles for article (PubMed ID: 20692814)

  • 41. Metabolic effects of the atypical antipsychotics.
    Wooten J
    South Med J; 2007 Aug; 100(8):771-2. PubMed ID: 17713300
    [No Abstract]   [Full Text] [Related]  

  • 42. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis.
    Zhang Y; Liu Y; Su Y; You Y; Ma Y; Yang G; Song Y; Liu X; Wang M; Zhang L; Kou C
    BMC Psychiatry; 2017 Nov; 17(1):373. PubMed ID: 29162032
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
    van Winkel R; De Hert M; Wampers M; Van Eyck D; Hanssens L; Scheen A; Peuskens J
    J Clin Psychiatry; 2008 Mar; 69(3):472-9. PubMed ID: 18348593
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.
    Stauffer V; Ascher-Svanum H; Liu L; Ball T; Conley R
    BMC Psychiatry; 2009 Mar; 9():13. PubMed ID: 19335905
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis.
    Almandil NB; Liu Y; Murray ML; Besag FM; Aitchison KJ; Wong IC
    Paediatr Drugs; 2013 Apr; 15(2):139-50. PubMed ID: 23519708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
    Correll CU; Manu P; Olshanskiy V; Napolitano B; Kane JM; Malhotra AK
    JAMA; 2009 Oct; 302(16):1765-73. PubMed ID: 19861668
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
    Leucht S; Cipriani A; Spineli L; Mavridis D; Orey D; Richter F; Samara M; Barbui C; Engel RR; Geddes JR; Kissling W; Stapf MP; Lässig B; Salanti G; Davis JM
    Lancet; 2013 Sep; 382(9896):951-62. PubMed ID: 23810019
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
    Citrome L; Volavka J
    Postgrad Med; 2004 Oct; 116(4):49-51, 55-9, 63. PubMed ID: 15510593
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review.
    Simon V; van Winkel R; De Hert M
    J Clin Psychiatry; 2009 Jul; 70(7):1041-50. PubMed ID: 19653979
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
    Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
    N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.
    Geddes J; Freemantle N; Harrison P; Bebbington P
    BMJ; 2000 Dec; 321(7273):1371-6. PubMed ID: 11099280
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
    Wu RR; Zhao JP; Liu ZN; Zhai JG; Guo XF; Guo WB; Tang JS
    Psychopharmacology (Berl); 2006 Jul; 186(4):572-8. PubMed ID: 16601995
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
    Leucht S; Crippa A; Siafis S; Patel MX; Orsini N; Davis JM
    Am J Psychiatry; 2020 Apr; 177(4):342-353. PubMed ID: 31838873
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.
    Kelly DL; Kreyenbuhl J; Love RC; Van-Duong Q; Conley RR
    J Clin Psychiatry; 2003 Sep; 64(9):1133-4. PubMed ID: 14628994
    [No Abstract]   [Full Text] [Related]  

  • 55. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.
    Cohen D; Bonnot O; Bodeau N; Consoli A; Laurent C
    J Clin Psychopharmacol; 2012 Jun; 32(3):309-16. PubMed ID: 22544019
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
    De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
    CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons.
    Kishimoto T; Hagi K; Nitta M; Kane JM; Correll CU
    World Psychiatry; 2019 Jun; 18(2):208-224. PubMed ID: 31059621
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.
    Lublin H; Haug HJ; Koponen H; Sigmundsson T; Kolb SA
    World J Biol Psychiatry; 2009; 10(4 Pt 3):710-8. PubMed ID: 18803070
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
    Smith RC; Leucht S; Davis JM
    Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
    Atmaca M; Kuloglu M; Tezcan E; Ustundag B
    J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.